Biocept is offering 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock at a combined price $1.20 per share and warrant.
The company said the financing will further support its strategy of translating its genome editing platforms into potential therapeutics and drug-discovery solutions.
Eagle said it will use the funding to further develop its software platform for analyzing genomic and microbiomic data at scale.
The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.
The transaction included the conversion of a $2 million note, eliminating the company's debt, as well as the sale of $1 million in preferred shares.
The company intends to use the funding to expand its operations and support sales of its Cyto-Mine single-cell analysis system.
The funds will help commercialize Ador's NATlab reader, a point-of-care MDX platform for sample-to-answer identification of specific infectious diseases.
The firm said it raised €55.5 million to fund the expansion of its Idylla test platform, its sales and marketing activities, and other general corporate purposes.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
The firm will use the funds to improve market entry and expedite development of its artificial intelligence-based software that analyzes single-cell data.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.